Astragaloside IV Ameliorates Diabetic Kidney Disease via Inhibiting MAPK Pathway and Alleviating Metabolic Dysregulation.
文献摘要
Diabetic kidney disease (DKD) is a severe diabetic microvascular complication with a complex pathogenesis and progression driven by renal fibrosis and inflammation. As a condition, DKD imposes a heavy clinical burden. Astragaloside IV (AS-IV), the main active component of Astragalus membranaceus , exhibits renoprotective potential in DKD, but its molecular mechanisms remain unclear. This study combined network pharmacology, molecular docking, and in vivo validation in db/db mice in order to explore AS-IV's therapeutic effect on DKD and the mechanisms by which it alleviates inflammation and fibrosis. The efficacy of AS-IV was evaluated via glucose metabolism, urinary protein, hepatic/renal function, and renal histopathology using H&E, PAS, Masson staining, and transmission electron microscopy. The expressions of the MAPK pathway, fibrosis and inflammation-related molecules were detected by ELISA, Western blot, RT-qPCR, immunohistochemistry and immunofluorescence. In addition, non-targeted metabolomics was used to explore metabolic regulation. Network pharmacology identified the MAPK pathway as a core target, and molecular docking confirmed AS-IV's strong binding to MAPK1/MAPK3. In vivo, AS-IV improved glucose metabolism, reduced albuminuria, alleviated renal histological damage, inhibited ERK/JNK/p38 phosphorylation in the MAPK pathway, downregulated fibrosis-related proteins (TGF-β1, α-SMA, Collagen I/IV) and suppressed NF-κB-mediated inflammation. It furthermore ameliorated metabolic disorders, and exhibited a particular efficacy in doing so for amino acid metabolism. Collectively, AS-IV retards DKD progression by both exerting antifibrotic/anti-inflammatory effects and correcting metabolic dysregulation via inhibition of the MAPK pathway. These mechanisms provide a theoretical basis for the clinical application of AS-IV in DKD.